AzTrials
AzTrials

Diffuse Midline GliomaPhase 1/2PRiME IINCT06639607

PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma

A Phase 1/2 study testing PEP-CMV vaccine, Tetanus booster and Nivolumab in people with Diffuse Midline Glioma and Diffuse Midline High-grade Glioma, run by Washington University School of Medicine at 3 sites in United States.

Suspended

Paused. Enrolment is on hold for now and may resume.

Official record
Search all trials

Trial summary

This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint… Read more about this study

Who is it for?
Ages 4 to 25 years
What is being tested?
PEP-CMV vaccine, Tetanus booster and Nivolumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
68 participants
Where
3 sitesUnited States
Study dates
30 Sep 2026to 30 Jun 2051
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 4 to 25 years
  • All sexes
  • No healthy volunteers
  • Child, Adult

Who may be able to join

  • Patients must be ≥4 and ≤25 years of age (inclusive) at the time of study enrollment
  • Metastatic Disease: Patients with M+ disease are eligible.
  • Adequate bone marrow function defined as:
  • ANC (Absolute neutrophil count) ≥ 1000/µl.
  • Platelets ≥ 75,000/µl.
  • Hemoglobin > 8 g/dL. (may be supported)
Show all 49Show fewer
  • Adequate renal function defined as:
  • Creatinine clearance or radioisotope GFR ≥ 70ml/min/1.73 m^2 OR A serum creatinine based on age/gender as listed in the protocol. Note: The threshold creatinine values in this table were derived from the Schwartz formula for estimating GFR utilizing child length and stature data published by the CDC.
  • Adequate liver function defined as:
  • Total bilirubin ≤1.5 times institutional ULN
  • AST(SGOT) ≤3 × institutional upper limit of normal
  • ALT(SGPT) ≤3 × institutional upper limit of normal
  • The effects of PEP-CMV and nivolumab on the developing human fetus are unknown. For this reason, female participants of childbearing potential and male participants who are sexually active must agree to use adequate contraception prior to study entry, for the duration of study participation, and for at least 6 months after completion of study participation. Pregnancy tests must be obtained in girls and women who are post-menarchal at screening, at least 24 hours prior to the first dose of nivolumab and every 4 weeks (+/- 1 week) regardless of dosing schedule. An extension up to 72 hours prior to the start of study treatment is permissible in situations where results cannot be obtained within the standard 24 hour window. Should a female participant become pregnant or suspect she is pregnant while participating in this study, or should a male participant suspect he has fathered a child, s/he must inform the treating physician immediately.
  • Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants. All patients and/or their parents or legal guardians must sign an IRB approved written informed consent document.
  • Inclusion Criteria for Patients with Newly-Diagnosed High-Grade Gliomas (HGG) and Newly-Diagnosed (DMG) (Stratum I):
  • Stratum I patients must have histologically confirmed, newly-diagnosed HGG (such as anaplastic astrocytoma, glioblastoma) or newly-diagnosed DMG (such H3K27M mutant diffuse midline glioma).
  • Patients with a newly-diagnosed HGG/DMG must enroll within 6 weeks of their final dose of standard radiation therapy with or without chemotherapy.
  • Patients with primary spinal cord tumors are eligible
  • Patients with a radiographically typical diffuse intrinsic pontine glioma (DIPG), a subset of DMG, defined as a tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons, are eligible without histologic confirmation.
  • Patients with brainstem lesions that do not meet these radiographic criteria will be eligible if there is histologic confirmation of an infiltrating astrocytoma WHO grades II-IV (excluding grade II BRAF altered gliomas).
  • Karnofsky >50 for patients > 16 years of age or Lansky >50 for patients <16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Patients must have adequate neurologic function defined as:
  • Patients with neurological deficits should have deficits that are stable for a minimum of 1 week prior to enrollment.
  • Patients must have received no prior therapy other than surgery, radiation, chemotherapy during radiotherapy and/or steroids (dexamethasone with goal to wean dexamethasone throughout protocol therapy), with the following qualifications:
  • Patients with a newly diagnosed high-grade glioma or DMG must enroll within 42 days after their final dose of standard of care radiation therapy with or without chemotherapy.
  • Patients with HGG or DMG are permitted, but not required, to have received chemotherapy during radiation. Bevacizumab is permitted prior to enrollment in patients with DMG or HGG. Patients must have received their last dose of bevacizumab at least 14 days prior to enrollment.
  • For HGG patients, Patients must have received radiotherapy at a standard dose of ~54 Gy in ~1.8 Gy fractions for approximately 6 weeks with an acceptable variance of 10%. Radiation therapy must have begun no later than 30 days after the date of definitive surgery.
  • For patients with DIPG, Patients must have received radiotherapy at a standard dose of radiotherapy of ~54 Gy in ~1.8 Gy daily fractions for approximately 6 weeks with an acceptable variance rate of 10%. Radiation therapy must have begun no later than 30 days after the date of radiographic diagnosis or biopsy.
  • For patients with spinal cord HGG/DMG: Patients must have received radiotherapy at a standard dose of ~54 Gy in ~1.8 Gy fractions for approximately 6-7 weeks with an acceptable variance rate of 10%.
  • For patients with metastatic disease: Patients may have received standard dose craniospinal therapy.
  • Inclusion Criteria for patients with recurrent/progressive HGG/DMG (stratum II) or recurrent /progressive MB or EPN (stratum III):
  • Recurrent MB, EPN, DMG or HGG: Patients must have a diagnosis of medulloblastoma that is recurrent, progressive or refractory. All patients must have histological verification of a MB, EPN, DMG or HGG at either original diagnosis or relapse.
  • Patients must have adequate pretrial tumor material available (except DMG).
  • Patients must have measurable disease defined as a lesion that can be measured in two perpendicular diameters on MRI.
  • Karnofsky ≥ 50% for patients >16 years of age or Lansky ≥ 50 for patients ≤ 16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
  • Adequate neurologic function defined as:
  • Patients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to enrollment.
  • Patients with current seizure disorders may be enrolled if seizures are well-controlled on antiepileptic therapies.
  • Previous enrollment and treatment on an interventional clinical trial(s) is allowed.
  • Patients must have received prior disease-directed therapy including radiotherapy for their initial diagnosis of MB, EPN, HGG, or DMG, unless the patient had a supratentorial EPN with GTR and radiation was not deemed necessary by the treating team.
  • Patients must have had their last fraction of:
  • Craniospinal irradiation (if completed), total body irradiation or radiation to ≥ 50% of pelvis > 3 months prior to enrollment.
  • Focal irradiation > 4 weeks prior to enrollment.
  • Patients must have received their last dose of myelosuppressive anticancer therapy at least 21 days prior to enrollment. Patients who have received nitrosoureas must have their last dose at least 42 days prior to enrollment.
  • Patients must have received their last dose of any immunotherapy agents at least 30 days prior to enrollment.
  • Patients must have received their last dose of non-myelosuppressive anticancer agents at least 7 days prior to study enrollment.
  • Patients must have received their last dose of any antibodies at least 21 days prior to enrollment.
  • Patients must have received their last dose of hematopoietic growth factors at least 14 days prior to enrollment for a long-acting growth factor (e.g. pegfilgrastim) or 7 days prior to enrollment for short-acting growth factor.
  • At least 90 days must have elapsed after an autologous stem cell infusion.

Who cannot join

  • Pregnant or breast-feeding women will not be entered on this study due to known or unknown risks of fetal and teratogenic adverse events as seen in animal/human studies. Pregnancy tests must be obtained in girls and women who are post-menarchal at least 7 days prior to study enrollment. Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method.
  • Active infection requiring treatment.
  • Patients with malignancy related to HIV or solid organ transplant: known history of HIV, HBV surface antigen positivity or positive HCV antibody are not eligible. Viral testing is not required unless clinically indicated in patients without a known history
  • Known immunosuppressive disease.
  • Patients with active unrelated systemic illness including but not limited to renal, hepatic cardiac (congestive cardiac failure, myocardial infarction, myocarditis), or moderate to severe pulmonary problems generally defined by need for medical intervention (e.g., oxygen, medications) and/or limiting activities of daily living (generally CTCAE Grade 2 or higher) or shortness of breath with limited exertion are not eligible. Pulmonary conditions include (but are not limited to) COPD, asthma, and hemi-pneumectomy
  • Patients receiving concomitant immunosuppressive agents for medical conditions; inhaled corticosteroids for asthma are allowed.
Show all 12Show fewer
  • Patients receiving concomitant tumor-directed therapy.
  • Patients receiving any other investigational drug therapy.
  • Previous enrollment and treatment on an interventional clinical trial (Stratum 1 only).
  • Patients on dexamethasone > 0.1 mg/Kg/day up to maximum dose of 4 mg/day or equivalent.
  • Patients with inability to return for follow-up visits or obtain follow-up studies required to assess toxicity to therapy.
  • Patients at high risk for imminent neurologic decline due to extensive bulk disease, midline shift, or herniation on MRI. These patients should be discussed with the Study Chair.

Trial locations and contacts

3 sites in 1 country.

United States3 sites

  • Duke University Medical Center

    Durham, North Carolina, 27710

  • MD Anderson Cancer Center

    Houston, Texas, 77030

  • Washington University School of Medicine

    St Louis, Missouri, 63110

Other trials in United States

About this study

Official title: Phase 1/2 Trial of PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma (PRiME II)

This is a multisite, phase I/II clinical trial in children and young adults with newly-diagnosed high-grade glioma (HGG), diffuse midline glioma (DMG) and recurrent HGG/DMG, Medulloblastoma (MB), or ependymoma (EPN) to determine the safety, immunogenicity, and efficacy of a CMV-directed peptide vaccine plus checkpoint blockade.

Being tested
PEP-CMV vaccine, Tetanus booster, Nivolumab, Temozolomide
Keywords
PEP-CMV, Peptide vaccine, Immunotherapy, Nivolumab, DIPG, Vaccine therapy, Pp65, Recurrent, Newly diagnosed, Diffuse intrinsic pontine glioma
Medical subject headings
Medulloblastoma, Ependymoma, Recurrence, Diffuse Intrinsic Pontine Glioma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PEP-CMV vaccineBiological

    Intra-dermally administered half in the RIGHT groin and half in the LEFT groin.

  • Tetanus boosterBiological

    Also called Td booster

    Td 5 flocculation units, Lf

  • NivolumabBiological

    Administered intravenously

  • TemozolomideDrug

    Administered orally

Study groups in NCT06639607
Study groupRoleWhat they receive
Phase I Stratum I: Temozolomide + Nivolumab + PEP-CMV vaccine + Td boosterExperimentalPatients with newly-diagnosed high-grade glioma or DMG may be enrolled any time within 42 days after completing radiation. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
Receives: Biological: PEP-CMV vaccine; Biological: Tetanus booster; Biological: Nivolumab; Drug: Temozolomide
Phase I Stratum II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td boosterExperimentalPatients with recurrent/progressive HGG or DMG with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
Receives: Biological: PEP-CMV vaccine; Biological: Tetanus booster; Biological: Nivolumab; Drug: Temozolomide
Phase I Stratum III: Temozolomide + Nivolumab + PEP-CMV vaccine + Td boosterExperimentalPatients with recurrent/progressive MB or EPN with measurable disease can be enrolled at any point following recurrence regardless of any prior therapy. Cycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression (up to 10 years). Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
Receives: Biological: PEP-CMV vaccine; Biological: Tetanus booster; Biological: Nivolumab; Drug: Temozolomide
Phase II: Temozolomide + Nivolumab + PEP-CMV vaccine + Td boosterExperimentalCycle 1 (Induction cycle) is 77±2 days. Will receive 1 course of temozolomide 200 mg/m^2/day x 5 days on Days 1-5 of cycle 1 \& receive PEP-CMV vaccine at dose level 1 (250 μg/m^2) on Days 21, 35 ±2 days, and 49 ±2 days. After the induction cycle, each subsequent cycle is 28 days. Starting in cycle 2, PEP-CMV vaccine is administered every 28 days on day 1 of each course. Patient can continue to receive PEP-CMV every 28 days until recurrence/progression. Patients 18 and older will receive a tetanus (Td) booster at the time of enrollment. Immunotherapy begins with a Td pre-conditioning vaccine delivered 6-24 hours prior to the first vaccine on day 21. Patients will also receive nivolumab 3 mg/kg IV on day 14±1 day then every 14 days ±2 days thereafter.
Receives: Biological: PEP-CMV vaccine; Biological: Tetanus booster; Biological: Nivolumab; Drug: Temozolomide

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Proportion of patients with unacceptable toxicity

    An unacceptable toxicity will be defined as any life-threatening toxicity ≥ Grade 3 that is possibly, probably, or definitely related to the PEP CMV vaccine. There are exceptions listed in the protocol

    Measured: From the first vaccine (day 21) through 2 weeks after the third vaccine (day 49) (estimated to be 42 days)

Secondary outcomes (4)

  1. Mean change in immune response as measured by ELISPOT (IFN-γ) (Phase I only)

    For this analysis, the newly diagnosed patients (n=10) will be analyzed separately from the recurrent patients (n=20)

    Measured: Baseline (prior to nivolumab infusion on day 14), cycle 1 day 20, before vaccine #4 (cycle 2 day 1, each cycle is 28 days), every 2 cycles (each cycle is 28 days), and end of treatment (up to 10 years)

  2. Median change in immune response as measured by ELISPOT (IFN-γ) (Phase I only)

    For this analysis, the newly diagnosed patients (n=10) will be analyzed separately from the recurrent patients (n=20)

    Measured: Baseline (prior to nivolumab infusion on day 14), cycle 1 day 20, before vaccine #4 (cycle 2 day 1, each cycle is 28 days), every 2 cycles (each cycle is 28 days), and end of treatment (up to 10 years))

  3. Median overall survival (OS)

    OS is defined as time between the start of TMZ Day 1 and death.

    Measured: Through completion of follow-up (estimated to be 20 years)

  4. Median progression-free survival (PFS)

    PFS is defined as the time between the start of TMZ on Day 1 and first documentation of death or disease progression/recurrence. Patients remaining alive without disease progression will have PFS censored at their last follow-up.

    Measured: Through completion of follow-up (estimated to be 20 years)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2024
  2. Study start30 Sep 2026 (estimated)
  3. Primary completion31 Aug 2031 (estimated)
  4. Study completion30 Jun 2051 (estimated)

Why it stopped: Drugs/Equipment Unavailable

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
A total of 30 patients (n=10 in each stratum) will be enrolled for the Phase I portion of this study. An additional 28 patients will be enrolled for the Phase II portion of this study.
Masking
None (open label)
Enrolment
68 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06639607
Sponsor's protocol ID
202410163
Other IDs
R01CA296813
Acronym
PRiME II
Status last verified
Sep 2026
First submitted
7 Oct 2024
Last updated
11 Sep 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data collected during the trial, after deidentification may be shared between enrolling sites (WashU, Duke, MD Anderson).

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing PEP-CMV vaccine, Tetanus booster and Nivolumab in people with Diffuse Midline Glioma and Diffuse Midline High-grade Glioma, run by Washington University School of Medicine at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 49 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: paused, as of the sponsor's last update on 11 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Proportion of patients with unacceptable toxicity (time frame: From the first vaccine (day 21) through 2 weeks after the third vaccine (day 49) (estimated to be 42 days)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06639607.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Sep 2026; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in